J9313 – Injection, moxetumomab pasudotox-tdfk, 0.01 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9313
- Long description
- Injection, moxetumomab pasudotox-tdfk, 0.01 mg
- Short description
- Inj., lumoxiti, 0.01 mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1DChemotherapy- ASC
- Approved for ambulatory surgical centers
- Added
- October 1, 2019
- Last change
- October 1, 2019 – No change
Frequently asked questions
What is HCPCS code J9313?
J9313 is a HCPCS Level II code for injection, moxetumomab pasudotox-tdfk, 0.01 mg.
Does Medicare cover J9313?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9305 – Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 – Injection, pertuzumab, 1 mg
- J9307 – Injection, pralatrexate, 1 mg
- J9308 – Injection, ramucirumab, 5 mg
- J9309 – Injection, polatuzumab vedotin-piiq, 1 mg
- J9310 – Injection, rituximab, 100 mg
- J9311 – Injection, rituximab 10 mg and hyaluronidase
- J9312 – Injection, rituximab, 10 mg
- J9314 – Injection, pemetrexed (teva), not therapeutically equivalent to j9305, 10 mg
- J9315 – Injection, romidepsin, 1 mg
- J9316 – Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg
- J9317 – Injection, sacituzumab govitecan-hziy, 2.5 mg
- J9318 – Injection, romidepsin, non-lyophilized, 0.1 mg
- J9319 – Injection, romidepsin, lyophilized, 0.1 mg
- J9320 – Injection, streptozocin, 1 gram
- J9321 – Injection, epcoritamab-bysp, 0.16 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.